factors associated with progression to myelofibrosis in patients with essential thrombocythemia
Published 1 month ago • 136 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
1:05
hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
-
2:45
an insight into clinical risk factors for progression in mpns
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:08
real-world analysis of the most study: factors impacting progression to mf in patients with et
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
3:53
essential thrombocythemia watch & wait | what patients should know
-
29:13
essential thrombocythemia: pathogenesis and management
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
3:29
unmet needs and therapeutic strategies in essential thrombocythemia
-
1:34
are thrombotic risk and progression in et predictable?
-
1:25
the current approach to managing patients with prefibrotic pmf
-
2:15
advances in the risk stratification and treatment of essential thrombocythemia
-
3:49
factors influencing mpn progression
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
1:28
comorbidities and treatment decisions in myelofibrosis
-
8:07
essential thrombocythemia: outcomes, unmet needs, and therapeutic strategies
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
4:18
identifying risk factors for thrombosis in mpns and treatment strategies
-
1:32
factors contributing to the pathogenesis of icaht